• Borges do Nascimento Israel Júnior IJ 0000-0001-5240-0493 University Hospital and School of Medicine, Universidade Federal de Minas Gerais, Belo Horiz, Thilo Caspar von Groote, Dónal P O'Mathúna, Hebatullah Mohamed Abdulazeem, Catherine Henderson, Umesh Jayarajah, Ishanka Weerasekara, Tina Poklepovic Pericic, Henning Edgar Gerald Klapproth, Livia Puljak, Nensi Cacic, Irena Zakarija-Grkovic, Silvana Mangeon Meirelles Guimarães, Alvaro Nagib Atallah, Nicola Luigi Bragazzi, Milena Soriano Marcolino, Ana Marusic, Ana Jeroncic, and International Task Force Network of Coronavirus Disease 2019 (InterNetCOVID-19).
• University Hospital and School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
• Plos One. 2020 Jan 1; 15 (9): e0239235.

AbstractNew evidence on the COVID-19 pandemic is being published daily. Ongoing high-quality assessment of this literature is therefore needed to enable clinical practice to be evidence-based. This review builds on a previous scoping review and aimed to identify associations between disease severity and various clinical, laboratory and radiological characteristics. We searched MEDLINE, CENTRAL, EMBASE, Scopus and LILACS for studies published between January 1, 2019 and March 22, 2020. Clinical studies including ≥10 patients with confirmed COVID-19 of any study design were eligible. Two investigators independently extracted data and assessed risk of bias. A quality effects model was used for the meta-analyses. Subgroup analysis and meta-regression identified sources of heterogeneity. For hospitalized patients, studies were ordered by overall disease severity of each population and this order was used as the modifier variable in meta-regression. Overall, 86 studies (n = 91,621) contributed data to the meta-analyses. Severe disease was strongly associated with fever, cough, dyspnea, pneumonia, any computed tomography findings, any ground glass opacity, lymphocytopenia, elevated C-reactive protein, elevated alanine aminotransferase, elevated aspartate aminotransferase, older age and male sex. These variables typically increased in prevalence by 30-73% from mild/early disease through to moderate/severe disease. Among hospitalized patients, 30-78% of heterogeneity was explained by severity of disease. Elevated white blood cell count was strongly associated with more severe disease among moderate/severe hospitalized patients. Elevated lymphocytes, low platelets, interleukin-6, erythrocyte sedimentation rate and D-dimers showed potential associations, while fatigue, gastrointestinal symptoms, consolidation and septal thickening showed non-linear association patterns. Headache and sore throat were associated with the presence of disease, but not with more severe disease. In COVID-19, more severe disease is strongly associated with several clinical, laboratory and radiological characteristics. Symptoms and other variables in early/mild disease appear non-specific and highly heterogeneous. Clinical Trial Registration: PROSPERO CRD42020170623.

37 keywords...

hide…